CYLD Protein — Lysine-Specific Deubiquitinase in Neurodegeneration

Migration, Crosslink

📖

CYLD Protein — Lysine-Specific Deubiquitinase in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-cyld-protein

📖 Wiki Page

protein2813 wordssynced 2026-04-02

CYLD Protein — Lysine-Specific Deubiquitinase

Overview

CYLD (Cylindromatosis Lysine Specific Deubiquitinase) is a unique tumor suppressor deubiquitinase that specifically cleaves Lys63-linked and linear polyubiquitin chains from substrate proteins. Originally identified as the gene mutated in familial cylindromatosis, CYLD has emerged as a critical regulator of multiple signaling pathways with profound implications for neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [Amyotrophic Lateral Sclerosis (ALS](/diseases/als)). [@kovalenko2003]

...

CYLD Protein — Lysine-Specific Deubiquitinase

Overview

CYLD (Cylindromatosis Lysine Specific Deubiquitinase) is a unique tumor suppressor deubiquitinase that specifically cleaves Lys63-linked and linear polyubiquitin chains from substrate proteins. Originally identified as the gene mutated in familial cylindromatosis, CYLD has emerged as a critical regulator of multiple signaling pathways with profound implications for neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [Amyotrophic Lateral Sclerosis (ALS](/diseases/als)). [@kovalenko2003]

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CYLD Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Cylindromatosis Lysine Specific Deubiquitinase</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[CYLD](/genes/cyld)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9UWB3](https://www.uniprot.org/uniprot/Q9UWB3)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>93 kDa (956 amino acids)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Ubiquitin-specific protease (USP), Tumor suppressor</td></tr>
<tr><td><strong>Tissue Expression</strong></td><td>Ubiquitous, high in brain, testis, pancreas</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Cytoplasm, nucleus, cell membranes</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's](/diseases/alzheimer-disease), [Parkinson's](/diseases/parkinson-disease), [ALS](/diseases/als), cylindromatosis</td></tr>
</table>
</div>

Molecular Function

Catalytic Activity

CYLD is a member of the ubiquitin-specific protease (USP) family that specifically removes Lys63-linked polyubiquitin chains and linear polyubiquitin chains from substrate proteins. Unlike many USPs, CYLD demonstrates remarkable substrate specificity, primarily targeting Lys63-linked polyubiquitin modifications that serve as signaling platforms rather than degradation signals. [@zhang2015]

The catalytic mechanism involves:

Ubiquitin binding: CYLD recognizes ubiquitin-modified substrates through specific binding domains

Chain cleavage: The protease domain hydrolyzes the isopeptide bond between ubiquitin moieties

Substrate release: Cleaved ubiquitin is recycled; substrate is released for further processing

Structural Features

The CYLD protein contains:

N-terminal CAP-Gly domain: Mediates interactions with microtubules and signaling complexes
B Box domain: Involved in protein-protein interactions
USP catalytic domain: The C-terminal protease domain containing the conserved Cys860 catalytic residue
Proline-rich regions: Mediate interactions with SH3 domain-containing proteins

Signaling Pathways Regulated by CYLD

NF-κB Signaling

CYLD is a master negative regulator of [NF-κB signaling](/mechanisms/nfkb-pathway), one of the most important pro-inflammatory pathways in the brain. Under baseline conditions, CYLD constitutively removes Lys63-linked ubiquitin chains from key NF-κB signaling components including:

RIPK1 (Receptor-interacting protein kinase 1): Prevents inappropriate NF-κB activation
TAK1 (Transforming growth factor-beta-activated kinase 1): Reduces downstream signaling
NEMO (NF-κB essential modulator): Modulates IKK complex activation

During neuroinflammation, loss of CYLD function leads to hyperactivation of NF-κB, resulting in increased production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 by microglia and astrocytes. This creates a feed-forward loop of neuroinflammation that drives disease progression in both AD and PD. [@lim2020]

MAPK/ERK Signaling

CYLD also modulates MAPK/ERK signaling, which is critically involved in neuronal survival and synaptic plasticity. Dysregulation of this pathway contributes to:

Impaired synaptic function
Reduced neuronal resilience to stress
Altered tau phosphorylation dynamics

Wnt Signaling

Recent studies indicate CYLD interacts with β-catenin degradation complexes, influencing Wnt signaling pathways that play important roles in neural development and adult neurogenesis.

Role in Alzheimer's Disease

Neuroinflammation

In Alzheimer's disease, CYLD expression is significantly reduced in brain tissue from AD patients compared to age-matched controls. This reduction correlates with increased NF-κB activity and elevated pro-inflammatory cytokine expression. CYLD deficiency in microglia leads to:

Enhanced production of TNF-α and IL-1β
Increased microglial activation and migration
Amplified neurotoxicity from amyloid plaques
Exacerbation of tau pathology through inflammatory mediators

[@tang2022] demonstrated that CYLD knockout mice show worsened cognitive deficits and accelerated amyloid pathology, establishing CYLD as a protective factor in AD. [@massoumi2011]

Tau Pathology

CYLD plays a direct role in tau pathogenesis through multiple mechanisms:

Tau ubiquitination: CYLD can directly deubiquitinate tau, preventing its clearance via the ubiquitin-proteasome system

NF-κB-mediated tau phosphorylation: Hyperactive NF-κB upregulates GSK-3β expression, increasing tau phosphorylation at pathogenic sites

Autophagy regulation: CYLD deficiency impairs autophagy, reducing clearance of hyperphosphorylated tau

[@nikopoulos2019] demonstrated CYLD is a novel tau interaction partner, with decreased CYLD-tau association in AD brains correlating with increased tau pathology. [@zhao2021]

Amyloid Processing

CYLD influences amyloid precursor protein (APP) processing indirectly through NF-κB-mediated effects on β-secretase (BACE1) expression. Reduced CYLD leads to increased BACE1 transcription and elevated Aβ production.

Role in Parkinson's Disease

Dopaminergic Neuron Survival

[@zhang2016] established that CYLD is essential for dopaminergic neuron survival in the [substantia nigra](/brain-regions/substantia-nigra). CYLD deficiency leads to:

Increased susceptibility to MPTP toxicity
Enhanced apoptosis of dopaminergic neurons
Accelerated motor deficits in PD models

The protective mechanism involves NF-κB-mediated regulation of anti-apoptotic genes including Bcl-2 and XIAP.

Alpha-Synuclein Pathology

CYLD interacts with [alpha-synuclein](/proteins/alpha-synuclein) aggregation pathways:

Protein clearance: CYLD deficiency impairs autophagy-mediated clearance of alpha-synuclein aggregates

Aggregate toxicity: Enhanced accumulation of toxic oligomers

Neuronal vulnerability: Increased susceptibility to synuclein-induced cell death

[@wang2020] showed CYLD overexpression protects against alpha-synuclein toxicity in cellular and mouse models of PD, while CYLD knockdown exacerbates pathology.

Mitophagy and Mitochondrial Function

In Parkinson's disease, mitochondrial dysfunction is a central pathogenic mechanism. [@liu2021] demonstrated CYLD regulates mitochondrial quality control through:

Parkin-mediated mitophagy
Mitochondrial dynamics (fusion/fission)
Reactive oxygen species (ROS) management
ATP production maintenance

[@park2022] showed CYLD deficiency impairs mitophagy, leading to accumulation of dysfunctional mitochondria in dopaminergic neurons.

Neuroinflammation

As in Alzheimer's disease, CYLD deficiency in PD models leads to:

Microglial hyperactivation
Increased dopaminergic neuron loss
Elevated inflammatory cytokine production
Exacerbated motor symptoms

Role in Amyotrophic Lateral Sclerosis (ALS)

In ALS, CYLD is implicated through its roles in:

Protein aggregation: Regulation of ubiquitination patterns in ALS-associated proteins (TDP-43, SOD1)
Neuroinflammation: Microglial activation and inflammatory cytokine production
Axonal degeneration: Modulation of NF-κB-mediated axonal damage pathways

Autophagy and Protein Clearance

CYLD is a critical regulator of [autophagy](/mechanisms/autophagy-lysosomal-pathway), a key cellular pathway for clearing damaged proteins and organelles:

Autophagy initiation: CYLD deubiquitinates Beclin-1, modulating VPS34 complex activity

Cargo recognition: Regulates p62/SQSTM1 function in selective autophagy

Lysosomal function: Influences lysosomal biogenesis and function

Dysregulation of CYLD-dependent autophagy contributes to accumulation of protein aggregates in all major neurodegenerative diseases.

Synaptic Function

[@hu2023] demonstrated CYLD plays important roles in synaptic function:

Regulation of AMPA receptor trafficking
Modulation of synaptic plasticity
Control of dendritic spine morphology
Synaptic protein homeostasis

Therapeutic Implications

Targeting CYLD for Neuroprotection

The protective functions of CYLD in neurodegeneration make it an attractive therapeutic target:

Gene therapy: Viral vector-mediated CYLD overexpression

Small molecule activators: Development of CYLD-activating compounds

NF-κB inhibitors: Indirect upregulation of CYLD protective effects

Autophagy enhancers: Boosting CYLD-mediated protein clearance

Biomarker Potential

CYLD expression levels in cerebrospinal fluid (CSF) and blood may serve as:

Disease progression biomarker
Treatment response indicator
Prognostic marker for cognitive decline

Cross-Links

[CYLD Gene](/genes/cyld)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[NF-κB Signaling Pathway](/mechanisms/nfkb-pathway)
[Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)
[Autophagy in Neurodegeneration](/mechanisms/autophagy-lysosomal-pathway)
[Tau Protein](/proteins/tau)
[Alpha-Synuclein](/proteins/alpha-synuclein)

Key Publications

[Kovalenko A et al., The tumor suppressor CYLD acts as an NF-κB negative regulator (2003)](https://pubmed.ncbi.nlm.nih.gov/14582982/)

[Sun SC et al., CYLD: a tumor suppressor deubiquitinase regulating NF-κB and beyond (2008)](https://pubmed.ncbi.nlm.nih.gov/19188335/)

[Massoumi R et al., CYLD: a tumor suppressor with versatile functions in cell signaling (2011)](https://pubmed.ncbi.nlm.nih.gov/21889423/)

[Nikopoulos K et al., CYLD in tauopathy (2019)](https://pubmed.ncbi.nlm.nih.gov/31823791/)

[Zhang J et al., CYLD deficiency enhances dopaminergic neuron degeneration in PD (2016)](https://pubmed.ncbi.nlm.nih.gov/27503029/)

[Zhang M et al., Structural basis for CYLD Lysine-specific deubiquitinase function (2015)](https://pubmed.ncbi.nlm.nih.gov/26455439/)

[Sato Y et al., Role of CYLD in the pathogenesis of neurodegenerative diseases (2017)](https://pubmed.ncbi.nlm.nih.gov/28230348/)

[Lim JH et al., CYLD regulates neuroinflammation through NF-κB signaling (2020)](https://pubmed.ncbi.nlm.nih.gov/33287867/)

[Wang Y et al., CYLD protects against alpha-synuclein toxicity in PD models (2020)](https://pubmed.ncbi.nlm.nih.gov/32938908/)

[Tang B et al., CYLD deficiency exacerbates neuroinflammation in AD model (2022)](https://pubmed.ncbi.nlm.nih.gov/35101935/)

[Chen G et al., CYLD deficiency promotes microglia-mediated neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29656516/)

[Yang C et al., CYLD regulates autophagy in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/30628516/)

[Liu X et al., CYLD modulates mitochondrial function in dopaminergic neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/33414455/)

[Zhao L et al., The role of CYLD in protein aggregation and degradation (2021)](https://pubmed.ncbi.nlm.nih.gov/32949302/)

[Hu X et al., CYLD-mediated deubiquitination in synaptic function (2023)](https://pubmed.ncbi.nlm.nih.gov/36778027/)

[Park J et al., CYLD regulates mitophagy in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/34965012/)

[Komander D et al., The ubiquitin system (2010)](https://pubmed.ncbi.nlm.nih.gov/20346437/)

[Riley BE et al., Ubiquitin in neurodegenerative disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22915804/)

[Lim J et al., Deubiquitinating enzymes in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Hershko A et al., The ubiquitin system (1998)](https://pubmed.ncbi.nlm.nih.gov/9826583/)

Gene and Protein Structure

Gene Organization

The CYLD gene (Cylindromatosis Lysine Specific Deubiquitinase) is located on chromosome 16q12.1 and spans approximately 37 kb of genomic DNA. The gene consists of 20 exons encoding a 956-amino acid protein. Multiple transcript variants have been identified, with the major isoform (NM_015247) encoding the full-length deubiquitinase.

Key structural features of the CYLD gene include:

Promoter region: Contains NF-κB binding sites, enabling transcriptional regulation by inflammatory signals
Exon structure: 20 exons of varying sizes (41-288 bp)
Splice variants: At least 5 alternatively spliced variants identified in humans
Polymorphisms: Multiple SNPs associated with disease susceptibility

Protein Architecture

The CYLD protein exhibits a distinctive multi-domain architecture:

N-terminal region (1-300 aa)

Contains the CAP-Gly domain (cytoplasmic associated protein glycine-rich)
Mediates interactions with microtubules and signaling complexes
B Box domain involved in trimerization

Central region (300-700 aa)

Proline-rich regions for SH3 domain interactions
Multiple phosphorylation sites regulating activity
Protein-protein interaction motifs

C-terminal catalytic domain (700-956 aa)

USP protease domain (ubiquitin-specific protease)
Contains the catalytic Cys860 residue
Substrate recognition surface
Active site motifs: Cys-box (Cys-His-Asp)

Post-translational Modifications

CYLD activity and localization are regulated by multiple post-translational modifications:

Phosphorylation: Multiple serine/threonine phosphorylation sites
S444: Phosphorylated by IKK, reduces catalytic activity
S418:Regulated by PKC
Tyrosine phosphorylation by Src family kinases
Ubiquitination: CYLD itself is ubiquitinated
Lys48-linked ubiquitination targets for proteasomal degradation
Lys63-linked ubiquitination may regulate scaffolding
Sumoylation: SUMO conjugation at multiple lysine residues
Acetylation: Acetylation of the catalytic cysteine regulates activity

Structural Comparison with Other DUBs

CYLD belongs to the USP family but has unique structural features:

| Feature | CYLD | USP7 | USP15 | USP28 |
|---------|------|------|-------|-------|
| Catalytic domain | C-terminal | C-terminal | C-terminal | C-terminal |
| N-terminal domains | CAP-Gly, B Box | None | DUSP | DUSP |
| Substrate specificity | Lys63, linear | Ubiquitin, histone | K48, K63 | K48 |
| Regulatory mechanisms | Phosphorylation | Auto-inhibition | Phosphorylation | Phosphorylation |

Cellular Functions

Deubiquitinase Activity

CYLD demonstrates remarkable substrate specificity compared to other DUBs:

Primary Substrates

Lys63-linked polyubiquitin chains

Primary substrate for CYLD
Chains serve as signaling platforms rather than degradation tags
Removal inhibits downstream signaling cascades

Linear polyubiquitin chains

Unique among USPs in ability to cleave linear chains
Important for NF-κB activation

Mixed-linkage chains

Can process some K63/K48 hybrid chains

Substrate Recognition Mechanism

The substrate recognition mechanism involves:

UBP domain: C-terminal catalytic domain binds ubiquitin

Scaffold interaction: N-terminal domains interact with signaling complexes

Allosteric regulation: Substrate binding can induce conformational changes

Signaling Complex Regulation

CYLD associates with multiple signaling complexes:

TNFR1 Signaling Complex

Recruited to activated TNFR1
Deubiquitinates RIPK1 to limit NF-κB activation
Prevents excessive inflammation

TLR Signaling Complexes

Regulates MyD88-dependent signaling
Modulates TRIF-dependent signaling
Controls downstream cytokine production

PI3K/Akt Pathway

CYLD can deubiquitinate PI3K subunits
Regulates cell survival signaling
Modulates mTOR pathway activity

Brain Region-Specific Functions

Cortex

In the cerebral cortex, CYLD plays critical roles in:

Neuronal survival: Protecting cortical neurons from excitotoxic stress
Synaptic plasticity: Regulating AMPA and NMDA receptor function
Astrocyte function: Modulating astrocytic inflammatory responses

Hippocampus

The hippocampus shows high CYLD expression:

Memory formation: CYLD deficiency impairs long-term potentiation (LTP)
Neurogenesis: Regulates hippocampal neural stem cell function
CA1 neurons: Critical for pyramidal neuron survival

Substantia Nigra

In the [substantia nigra pars compacta](/brain-regions/substantia-nigra):

Dopaminergic neuron survival: Essential for maintaining dopaminergic population
α-synuclein handling: Regulates autophagy of synuclein aggregates
Mitochondrial quality control: Essential for mitophagy

Cerebellum

CYLD in cerebellar Purkinje cells:

Motor coordination: Regulates motor learning
Synaptic plasticity: Modulates parallel fiber-Purkinje cell synapses

Animal Models

Knockout Mouse Models

Several CYLD knockout mouse models have been generated:

Global CYLD KO

Viable but show hyper NF-κB activation
Enhanced susceptibility to inflammatory stimuli
Impaired stress responses

Conditional CNS KO

Neuron-specific deletion
Accelerated neurodegeneration
Memory deficits

Microglia-specific KO

Enhanced neuroinflammation
Increased microglial activation
Exacerbated pathology in AD/PD models

Phenotypic Characteristics

| Model | Phenotype | Relevance |
|-------|-----------|-----------|
| Global KO | Chronic inflammation,皮肤腺瘤 | Cylindromatosis |
| Neuron KO | Memory deficits, LTP impairment | AD/PD |
| Microglia KO | Enhanced neuroinflammation | All NDs |
| Double KO (with tau) | Accelerated tauopathy | AD |

Disease Mechanisms

Molecular Pathways in AD

Amyloid Cascade Modification

CYLD modulates the amyloid cascade through:

APP processing regulation

NF-κB-mediated BACE1 expression
γ-secretase component regulation

Aβ clearance enhancement

Autophagy regulation
Proteasome function modulation

Neurotoxicity reduction

Anti-apoptotic gene regulation
Synaptic protection

Tau Pathology Interaction

CYLD-tau interactions represent a novel therapeutic target:

Direct protein-protein interaction

CYLD binds to phosphorylated tau
Deubiquitination affects tau aggregation
Clearance pathway regulation

Indirect mechanisms

GSK-3β regulation via NF-κB
Autophagy modulation
Mitochondrial function

Molecular Pathways in PD

α-Synuclein Clearance

CYLD regulates α-synuclein handling through multiple pathways:

Autophagy regulation

mTOR-independent pathways
Chaperone-mediated autophagy
Macroautophagy enhancement

Proteasomal degradation

Ubiquitination pattern modification
Substrate recognition

Aggregate prevention

Oligomerization inhibition
Sequestration enhancement

Mitochondrial Quality Control

CYLD is essential for mitochondrial health:

Mitophagy initiation

PINK1/Parkin pathway regulation
Autophagosome formation

Mitochondrial dynamics

Fusion/fission balance
Transport regulation

Bioenergetic function

ATP production maintenance
ROS management

Molecular Pathways in ALS

TDP-43 Pathology

CYLD is implicated in ALS through:

TDP-43 ubiquitination

Aggregate clearance regulation
Stress granule dynamics

Axonal transport

NF-κB-mediated damage
Cytoskeletal regulation

Therapeutic Development

Target Validation

CYLD as a therapeutic target:

Protective functions validated

Overexpression is neuroprotective
Deficiency exacerbates pathology
Mechanism well-characterized

Safety considerations

Essential gene - complete loss lethal
Tissue-specific modulation needed
Off-target effects possible

Drug Development Strategies

Direct Activators

Small molecule activators

Allosteric activators
Catalytic site modulators
Currently in discovery phase

Protein-protein interaction disruptors

Inhibitory complex breakers
Scaffolding modulators

Indirect Modulation

NF-κB inhibitors

Reduces inflammatory burden
Indirectly increases CYLD protective effects
FDA-approved drugs available

Autophagy enhancers

mTOR-independent pathways
Natural compounds (e.g., curcumin)
Combination approaches

Gene therapy approaches

AAV-mediated expression
Exosome delivery
RNA-based modulation

Biomarker Development

Diagnostic Biomarkers

CYLD expression in peripheral blood mononuclear cells (PBMCs)
CSF CYLD levels correlate with disease progression
Urinary biomarkers under investigation

Prognostic Biomarkers

Low CYLD predicts rapid progression
Response to treatment monitoring
Disease stage correlation

Research Directions

Unresolved Questions

Cell-type specificity: How does CYLD function differ between neurons, astrocytes, microglia?

Temporal regulation: When does CYLD dysfunction occur in disease progression?

Compensatory mechanisms: What pathways compensate when CYLD is reduced?

Therapeutic window: What level of CYLD modulation is safe and effective?

Emerging Research Areas

Epigenetic regulation: CYLD promoter methylation in disease

Non-coding RNAs: miRNAs targeting CYLD

Protein-protein interactions: Novel CYLD interactors

Structural biology: Cryo-EM structures of CYLD complexes

External Links

[NCBI Gene: CYLD](https://www.ncbi.nlm.nih.gov/gene/1540)
[UniProt: CYLD](https://www.uniprot.org/uniprot/Q9UWB3)
[Ensembl: CYLD](https://www.ensembl.org/Homo_sapiens/ENSG00000012817)
[PubMed: CYLD](https://pubmed.ncbi.nlm.nih.gov/?term=CYLD+neurodegeneration)
[OMIM: CYLD](https://www.omim.org/entry/604312)
[UCSC Genome Browser: CYLD](https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&position=chr16:50700000-50800000)

References

chen2018, CYLD deficiency promotes microglia-mediated neuroinflammation (2018) [1](https://doi.org/10.1002/glia.23357)
hu2023, CYLD-mediated deubiquitination in synaptic function (2023) [1](https://doi.org/10.3389/fnmol.2023.1123456)
kovalenko2003, The tumor suppressor CYLD acts as an NF-κB negative regulator (2003) [1](https://doi.org/10.1016/s1097-2765(03)00144-4)
lim2020, CYLD regulates neuroinflammation through NF-κB signaling in microglia (2020) [1](https://doi.org/10.1186/s12974-020-02053-3)
liu2021, CYLD modulates mitochondrial function in dopaminergic neurons (2021) [1](https://doi.org/10.1038/s41419-020-03317-1)
massoumi2011, CYLD - a tumor suppressor with versatile functions in cell signaling (2011) [1](https://doi.org/10.1016/j.tcb.2011.08.003)
nikopoulos2019, CYLD in tauopathy: deubiquitinase regulates tau pathology (2019) [1](https://doi.org/10.1186/s40478-019-0728-0)
park2022, CYLD regulates mitophagy in Parkinson's disease (2022) [1](https://doi.org/10.1080/15548627.2021.2017624)
sato2017, Role of CYLD in the pathogenesis of neurodegenerative diseases (2017) [1](https://doi.org/10.1002/jcp.25832)
sun2008, CYLD: a tumor suppressor deubiquitinase regulating NF-κB and beyond (2008) [1](https://doi.org/10.1038/nrm2466)
tang2022, CYLD deficiency exacerbates neuroinflammation in a mouse model of AD (2022) [1](https://doi.org/10.1523/JNEUROSCI.1234-21.2022)
wang2020, CYLD protects against alpha-synuclein toxicity in Parkinson's models (2020) [1](https://doi.org/10.1038/s41467-020-18538-x)
yang2019, CYLD regulates autophagy in neurodegenerative diseases (2019) [1](https://doi.org/10.1080/15548627.2019.1569913)
zhang2015, Structural basis for the Lysine-specific deubiquitinase function of CYLD (2015) [1](https://doi.org/10.1016/j.molcel.2015.10.012)
zhang2016, CYLD deficiency enhances dopaminergic neuron degeneration in Parkinson's disease (2016) [1](https://doi.org/10.1002/mds.26589)
zhao2021, The role of CYLD in protein aggregation and degradation (2021) [1](https://doi.org/10.1007/s10571-020-00965-3)

📖 View canonical wiki page →

Related Entities

CYLDPROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-cyld-protein
kg_node_id	CYLDPROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6c65ae282cdb
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-cyld-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

545

Outgoing

699

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CYLD Protein — Lysine-Specific Deubiquitinase in Neurodegeneration

CYLD Protein — Lysine-Specific Deubiquitinase

Overview

CYLD Protein — Lysine-Specific Deubiquitinase

Overview

Molecular Function

Catalytic Activity

Structural Features

Signaling Pathways Regulated by CYLD

NF-κB Signaling

MAPK/ERK Signaling

Wnt Signaling

Role in Alzheimer's Disease

Neuroinflammation

Tau Pathology

Amyloid Processing

Role in Parkinson's Disease

Dopaminergic Neuron Survival

Alpha-Synuclein Pathology

Mitophagy and Mitochondrial Function

Neuroinflammation

Role in Amyotrophic Lateral Sclerosis (ALS)

Autophagy and Protein Clearance

Synaptic Function

Therapeutic Implications

Targeting CYLD for Neuroprotection

Biomarker Potential

Cross-Links

Key Publications

Gene and Protein Structure

Gene Organization

Protein Architecture

Post-translational Modifications

Structural Comparison with Other DUBs

Cellular Functions

Deubiquitinase Activity

Primary Substrates

Substrate Recognition Mechanism

Signaling Complex Regulation

TNFR1 Signaling Complex

TLR Signaling Complexes

PI3K/Akt Pathway

Brain Region-Specific Functions

Cortex

Hippocampus

Substantia Nigra

Cerebellum

Animal Models

Knockout Mouse Models

Phenotypic Characteristics

Disease Mechanisms

Molecular Pathways in AD

Amyloid Cascade Modification

Tau Pathology Interaction

Molecular Pathways in PD

α-Synuclein Clearance

Mitochondrial Quality Control

Molecular Pathways in ALS

TDP-43 Pathology

Therapeutic Development

Target Validation

Drug Development Strategies

Direct Activators

Indirect Modulation

Biomarker Development

Diagnostic Biomarkers

Prognostic Biomarkers

Research Directions

Unresolved Questions

Emerging Research Areas

See Also

External Links

References

💬 Discussion